Tiotropium/olodaterol versus tiotropium in Japanese patients with COPD: results from the DYNAGITO study

References

• VogelmeierCFCrinerGJMartinezFJGlobal Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 report. GOLD executive summaryAm J Respir Crit Care Med2017195555758228128970
   PubMed Web of Science ®Google Scholar
• World Health OrganisationMortality and global health estimates2015 [cited 2018 Jan 12]. Available from: http://www.who.int/gho/mortality_burden_disease/en/Accessed February 12, 2018
   Google Scholar
• FukuchiYNishimuraMIchinoseMCOPD in Japan: the Nippon COPD Epidemiology studyRespirology20049445846515612956
   PubMed Web of Science ®Google Scholar
• WedzichaJACalverleyPMSeemungalTAThe prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromideAm J Respir Crit Care Med20081771192617916806
   PubMed Web of Science ®Google Scholar
• VogelmeierCHedererBGlaabTTiotropium versus salmeterol for the prevention of exacerbations of COPDN Engl J Med2011364121093110321428765
   PubMed Web of Science ®Google Scholar
• DecramerMLChapmanKRDahlROnce-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group studyLancet Respir Med20131752453324461613
   PubMed Web of Science ®Google Scholar
• WedzichaJADecramerMFickerJHAnalysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group studyLancet Respir Med20131319920924429126
   PubMed Web of Science ®Google Scholar
• KochAWatzHMaleki-YazdiMRComprehensive assessment of the safety of olodaterol 5 μg in the Respimat® device for maintenance treatment of COPD: comparison with the long-acting beta2-agonist formoterolNPJ Prim Care Respir Med20172716029061968
   PubMed Web of Science ®Google Scholar
• JoosGFAumannJLCoeckCA randomised, double-blind, four-way, crossover trial comparing the 24-h FEV1 profile for once-daily versus twice-daily treatment with olodaterol, a novel long-acting beta2-agonist, in patients with chronic obstructive pulmonary diseaseRespir Med2015109560661525776199
   PubMed Web of Science ®Google Scholar
• FeldmanGJBernsteinJAHamiltonANivensMCKorduckiLLaForceCThe 24-h FEV1 time profile of olodaterol once daily via Respimat® and formoterol twice daily via Aerolizer® in patients with GOLD 2-4 COPD: results from two 6-week crossover studiesSpringerplus2014341925187881
   PubMedGoogle Scholar
• FergusonGTFeldmanGJHofbauerPEfficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2–4 COPD: results from two replicate 48-week studiesInt J Chron Obstruct Pulmon Dis2014962964524966672
   PubMed Web of Science ®Google Scholar
• KochAPizzichiniEHamiltonALung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2–4 COPD: results from two replicate 48-week studiesInt J Chron Obstruct Pulmon Dis2014969771425045258
   PubMed Web of Science ®Google Scholar
• LangePHamiltonJ-LTetzlaffKTingNDeromEThe 24 hour lung function time profile of olodaterol once daily versus placebo and tiotropium in patients with moderate to very severe chronic obstructive pulmonary diseaseJ Pulm Resp Med20144196
   Google Scholar
• BuhlRMaltaisFAbrahamsRTiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4)Eur Respir J201545496997925573406
   PubMed Web of Science ®Google Scholar
• BeehKMWestermanJKirstenAMThe 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary diseasePulm Pharmacol Ther201532535925956072
   PubMed Web of Science ®Google Scholar
• SinghDFergusonGTBolitschekJTiotropium + olodaterol shows clinically meaningful improvements in quality of lifeRespir Med2015109101312131926320402
   PubMed Web of Science ®Google Scholar
• CalverleyPMAAnzuetoARCarterKTiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations: a double-blind, randomised, parallel-group, active-controlled, trialLancet Respir Med20186533734429605624
   PubMed Web of Science ®Google Scholar
• IchinoseMTaniguchiHTakizawaAThe efficacy and safety of combined tiotropium and olodaterol via the Respimat® inhaler in patients with COPD: results from the Japanese sub-population of the Tonado® studiesInt J Chron Obstruct Pulmon Dis2016112017202727621608
   PubMed Web of Science ®Google Scholar
• WexEKollakIDuechsMJNalineEWollinLDevillierPThe long-acting beta2-adrenoceptor agonist olodaterol attenuates pulmonary inflammationBr J Pharmacol2015172143537354725824824
   PubMed Web of Science ®Google Scholar
• CalverleyPMAAnzuetoARDusserDTreatment of exacerbations as a predictor of subsequent outcomes in patients with COPDInt J Chron Obstruct Pulmon Dis2018312971308
   Web of Science ®Google Scholar
• Japanese Respiratory SocietyCOPD Guidelines for Diagnosis and Treatment4th edJapanese Respiratory SocietyTokyo2013
   Google Scholar
• SuzukiMMakitaHItoYMClinical features and determinants of COPD exacerbation in the Hokkaido COPD cohort studyEur Respir J20144351289129724232696
   PubMed Web of Science ®Google Scholar
• Berrington de GonzálezADarbySRisk of cancer from diagnostic X-rays: estimates for the UK and 14 other countriesLancet200436334535115070562
   PubMed Web of Science ®Google Scholar
• KumamaruKKMachitoriAKobaRGlobal and Japanese regional variations in radiologist potential workload for computed tomography and magnetic resonance imaging examinationsJpn J Radiol201836427328129453512
   PubMed Web of Science ®Google Scholar
• IchinoseMKatoMTakizawaALong-term safety and efficacy of combined tiotropium and olodaterol in Japanese patients with chronic obstructive pulmonary diseaseRespir Investig2017552121129
   Web of Science ®Google Scholar